0001209191-18-016686.txt : 20180305
0001209191-18-016686.hdr.sgml : 20180305
20180305173241
ACCESSION NUMBER: 0001209191-18-016686
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180301
FILED AS OF DATE: 20180305
DATE AS OF CHANGE: 20180305
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gilmartin Geoffrey S.
CENTRAL INDEX KEY: 0001688268
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37695
FILM NUMBER: 18667586
MAIL ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
STREET 2: 4TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER NAME:
FORMER CONFORMED NAME: Gilmartin Greffrey S.
DATE OF NAME CHANGE: 20161024
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PROTEOSTASIS THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001445283
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
BUSINESS ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-225-0096
MAIL ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: PROTEOSTASIS THERAPEUTICS INC
DATE OF NAME CHANGE: 20080916
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-03-01
0
0001445283
PROTEOSTASIS THERAPEUTICS, INC.
PTI
0001688268
Gilmartin Geoffrey S.
C/O PROTEOSTASIS THERAPEUTICS, INC.
200 TECHNOLOGY SQUARE, 4TH FLOOR
CAMBRIDGE
MA
02139
0
1
0
0
Chief Development Officer
Employee Stock Option (Right to Buy)
3.11
2018-03-01
4
A
0
29900
0.00
A
2028-03-01
Common Stock
29900
29900
D
These securities shall vest and become exercisable in a series of installments, with the first installment to become exercisable for 25% of the
underlying common stock on February 1, 2019, and thereafter vesting and becoming exercisable in 12 quarterly installments as nearly equal as
practicable (as determined by the Issuer in its reasonable discretion), until such stock option becomes fully exercisable on February 1, 2022,
provided that the Reporting Person remains an employee of Issuer at all times during the applicable vesting period of such securities.
/s/ Janet L. Smart, Attorney-in-Fact
2018-03-05